Cargando…

Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?

Prescriptions for Benzodiazepines (BZDs) have risen continually. According to national statistics, the combination of BZDs with opioids has increased since 1999. BZDs (sometimes called “benzos”) work to calm or sedate a person by raising the level of the inhibitory neurotransmitter GABA in the brain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blum, K, Gold, M, Modestino, EJ, Baron, D, Boyett, B, Siwicki, D, Lott, L, Podesta, A, Roy, AK, Hauser, M, Downs, BW, Badgaiyan, RD
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865059/ https://www.ncbi.nlm.nih.gov/pubmed/31750006 http://dx.doi.org/10.15761/JSIN.1000196

Ejemplares similares

Americas’ opioid/psychostimulant epidemic would benefit from general population early identification of genetic addiction risk especially in children of alcoholics (COAs)
por: Blum, K, et al.
Publicado: (2019)

Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)
por: Blum, K, et al.
Publicado: (2019)

A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration
por: Blum, Kenneth, et al.
Publicado: (2021)

“Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic
por: Blum, Kenneth, et al.
Publicado: (2017)

Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission
por: Blum, Kenneth, et al.
Publicado: (2017)

High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial
por: Moran, Mark, et al.
Publicado: (2021)

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)
por: Kenneth, Blum, et al.
Publicado: (2018)

Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD
por: McLaughlin, Thomas, et al.
Publicado: (2018)

Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual
por: Blum, Kenneth, et al.
Publicado: (2020)

Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing
por: Modestino, Edward Justin, et al.
Publicado: (2022)

Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors
por: Gupta, Ashim, et al.
Publicado: (2022)

Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction
por: Blum, Kenneth, et al.
Publicado: (2015)

Can We Combat Reward Deficiency Behaviors (RDS) including Substance Use Disorder (SUD) through Genetic Risk Screening coupled with Precision Pro-Dopamine Regulation by Algorithmic matched Polymorphic Allelic Risks
por: Blum, Kenneth, et al.
Publicado: (2019)

Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation
por: Blum, Kenneth, et al.
Publicado: (2022)

“Pro-dopamine regulation (KB220Z™)” as a long-term therapeutic modality to overcome reduced resting state dopamine tone in opiate/opioid epidemic in America
por: Blum, K, et al.
Publicado: (2016)

Opioid and dopamine genes interact to predict precision naltrexone response in alcohol use disorder: Interpretation misfires
por: Blum, Kenneth, et al.
Publicado: (2021)

Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency
por: Edwards, Drew, et al.
Publicado: (2020)

Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis
por: Blum, Kenneth, et al.
Publicado: (2021)

Hypothesizing High Negative Emotionality as a Function of Genetic Addiction Risk Severity (GARS) Testing in Alcohol Use Disorder (AUD)
por: Blum, Kenneth, et al.
Publicado: (2020)

Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence
por: Blum, Kenneth, et al.
Publicado: (2013)

Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms
por: Blum, Kenneth, et al.
Publicado: (2015)

Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
por: Blum, Kenneth, et al.
Publicado: (2015)

Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case–Control Subjects
por: Blum, Kenneth, et al.
Publicado: (2022)

Detection of dopamine neurotransmission in “real time”
por: Badgaiyan, Rajendra D.
Publicado: (2013)

DNA Directed Pro-Dopamine Regulation Coupling Subluxation Repair, H-Wave(®) and Other Neurobiologically Based Modalities to Address Complexities of Chronic Pain in a Female Diagnosed with Reward Deficiency Syndrome (RDS): Emergence of Induction of “Dopamine Homeostasis” in the Face of the Opioid Crisis
por: Bajaj, Anish, et al.
Publicado: (2022)

Genetic Addiction Risk Score (GARS): Molecular Neurogenetic Evidence for Predisposition to Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2014)

Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone?
por: McLaughlin, Thomas, et al.
Publicado: (2017)

Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?
por: Blum, Kenneth, et al.
Publicado: (2023)

Dopamine and glucose, obesity, and reward deficiency syndrome
por: Blum, Kenneth, et al.
Publicado: (2014)

Offering a putative neurobiological “dopamine homeostatic” solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of “precision behavioral management”
por: Blum, Kenneth, et al.
Publicado: (2022)

Proposing FDA consideration for the treatment and prophylaxis of opioid and psychostimulant abuse to incorporate the induction of DNA guided dopamine homeostasis: Anti-reward deficiency restoration solution (ARDS)
por: Blum, Kenneth, et al.
Publicado: (2020)

Dopamine, behavior, and addiction
por: Wise, Roy A., et al.
Publicado: (2021)

Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2017)

Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
por: Ceccanti, Mauro, et al.
Publicado: (2022)

Dopamine signaling in food addiction: role of dopamine D2 receptors
por: Baik, Ja-Hyun
Publicado: (2013)

Opioids, dopamine, stress, and the addictions
por: Kreek, Mary Jeanne
Publicado: (2007)

Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of “Dopamine Homeostasis”
por: Blum, Kenneth, et al.
Publicado: (2022)

Polygenic and multi locus heritability of alcoholism: Novel therapeutic targets to overcome psychological deficits
por: Blum, Kenneth, et al.
Publicado: (2020)

Attenuated Tonic and Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity Disorder
por: Badgaiyan, Rajendra D., et al.
Publicado: (2015)

Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3lto1499jnb9nqjhup2k1l6dcf